A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 177 participants.

Also called NCT01262638

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 177 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01262638
Other papers using this trial's data
  • Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial Journal of the American College of Cardiology, 2013-09-24 DOI, PubMed 23770179

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01262638. Randomized; quadruple masking; primary purpose treatment. Start 2010-12 (registry gives no type); primary completion 2011-08-23 (actual). Results posted on 2021-03-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
Condition
Dyslipidemia
Intervention (Drug)
ETC-1002
Intervention (Drug)
Placebo
Lead sponsor
Esperion Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01262638
Content hash
a65d76cb6a3a61fd99dffed8f8f4265c5c81ec6034c510f9cd8073d0f2e9d638